Technical Analysis for HEB - Hemispherx BioPharma, Inc.

Grade Last Price % Change Price Change
grade F 0.1401 -5.34% -0.01
HEB closed down 5.34 percent on Friday, May 17, 2019, on 1.15 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical HEB trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Earnings Movers Other -5.34%
Wide Bands Range Expansion -5.34%
Oversold Stochastic Weakness -5.34%
Spinning Top Other -8.55%
Earnings Movers Other -8.55%
Wide Bands Range Expansion -8.55%
Oversold Stochastic Weakness -8.55%

Older signals for HEB ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Its products include Ampligen, which is under clinical development for the treatment of Chronic Fatigue Syndrome, Hepatitis B, human immunodeficiency virus (HIV), renal cell carcinoma, and malignant melanoma; Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of influenza and other emerging viral diseases. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.
Medicine Medical Specialties Pharmaceutical Infectious Diseases Influenza HIV Hepatitis B Renal Cell Carcinoma Drug Therapies Viral Diseases Antivirals Interferon Chronic Disorders
Is HEB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 0.35
52 Week Low 0.131
Average Volume 4,555,019
200-Day Moving Average 0.2103
50-Day Moving Average 0.1615
20-Day Moving Average 0.1599
10-Day Moving Average 0.1552
Average True Range 0.0211
ADX 30.14
+DI 32.7586
-DI 20.8249
Chandelier Exit (Long, 3 ATRs ) 0.2733
Chandelier Exit (Short, 3 ATRs ) 0.1943
Upper Bollinger Band 0.1991
Lower Bollinger Band 0.1207
Percent B (%b) 0.25
BandWidth 49.030644
MACD Line -0.0047
MACD Signal Line -0.0022
MACD Histogram -0.0025
Fundamentals Value
Market Cap 4.09 Million
Num Shares 29.2 Million
EPS -0.37
Price-to-Earnings (P/E) Ratio -0.38
Price-to-Sales 27.86
Price-to-Book 0.90
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.15
Resistance 3 (R3) 0.16 0.15 0.15
Resistance 2 (R2) 0.15 0.15 0.15 0.15
Resistance 1 (R1) 0.15 0.15 0.14 0.14 0.15
Pivot Point 0.14 0.14 0.14 0.14 0.14
Support 1 (S1) 0.14 0.14 0.13 0.14 0.13
Support 2 (S2) 0.13 0.14 0.13 0.13
Support 3 (S3) 0.13 0.13 0.13
Support 4 (S4) 0.13